(MENAFN- iCrowdNewsWire)
A new research document is added in HTF MI database of 123 pages, titled as 'Europe Drug Discovery Market 2020-2030 by Drug Type (Small Molecule, Biologics), Service (Medicinal, Biological, DMPK), Process, Technology, Therapeutic Area, End User, and Country: Trend Forecast and Growth Opportunity' with detailed analysis, Competitive landscape, forecast and strategies. Latest analysis highlights high growth emerging players and leaders by market share that are currently attracting exceptional attention.
Access sample report @
Summary
Europe drug discovery market was valued at $14.8 billion in 2020 and will grow by 8.3% annually over 2020-2030 owing the rising demand for specialty medicines, the surge in lifestyle-oriented diseases and the advancements in technology, the growing elderly population and the rising healthcare expenses, rising expenditure on R&D, and expiration of patents.
Highlighted with 36 tables and 64 figures, this 123-page report“Europe Drug Discovery Market 2020-2030 by Drug Type (Small Molecule, Biologics), Service (Medicinal, Biological, DMPK), Process, Technology, Therapeutic Area, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter's Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe drug discovery market in every aspect of the classification from perspectives of Drug Type, Service, Process, Technology, Therapeutic Area, End User, and Country.
Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
- Small Molecule Drugs
- Biologic Drugs
Based on Service, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
- Medicinal Chemical Services
- Biological Services
- Drug Metabolism and Pharmacokinetics (DMPK) Services
- Other Pharmaceutical Services
Based on Process, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
- Target Selection
- Target Validation
- Hit-To-Lead Identification
- Lead Optimization
- Candidate Validation
Based on Technology, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
- High Throughput Screening
- Combinatorial Chemistry
- Pharmacogenomics and Pharmacogenetics
- Nanotechnology
- Bioanalytical Instruments
- Biochips
- Bioinformatics
- Other Technologies
Based on Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
- Oncology
- Neurology
- Infectious and Immune System Diseases
- Digestive System Diseases
- Cardiovascular Diseases
- Diabetes
- Respiratory Disease
- Other Therapeutic Areas
Based on End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
- Pharmaceutical Companies
- Contract Research Organizations (CROs)
- Research Institutes
- Other End Users
Geographically, the following national/local markets are fully investigated:
- Germany
- UK
- France
- Spain
- Italy
- Russia
- Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Drug Type, Service, and Therapeutic Area over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories Inc.
Agilent Technologies Inc.
Astrazeneca plc
Bayer AG
Charles River Laboratories International Inc.
Eli Lilly and Company
Hoffmann-La Roche Ltd GlaxoSmithKline PLC
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
Shimadzu Corp
Thermo Fisher Scientific Inc.
Get Customization in the Report, Enquire Now @
….Continued
It's vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.
Purchase Single User License of this report at @
MENAFN04122021003318003403ID1103302325
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.